Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.125 +0.075 (+3.66%)
Streaming Delayed Price Updated: 1:31 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
37 38 Next >
42 Stocks Moving In Wednesday's Mid-Day Session
Gainers Sono Group N.V. (NASDAQ: SEV) shares jumped 66% to $24.90 after the company priced its IPO at $15 per share. EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares climbed... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
SAVA Stock Alert: The SEC Investigation That Has Cassava Sciences Cratering Today
Cassava Sciences (SAVA) stock is on the move Wednesday as investors react to reports of an SEC investigation over possible data manipulation. 
Via InvestorPlace
Topics Regulatory Compliance
Exposures Legal Regulatory
Cassava Sciences In Hot Water Again As Shorts Claim 'Extreme' Data Manipulation
In a filing, the short sellers claim the science backing Cassava's drug is impossible. 
Via Investor's Business Daily
Jim Cramer Likes This Stock Over Cassava Sciences And Biogen
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Cassava Sciences, Inc. (NASDAQ: 
Via Benzinga
Global Cancer Therapy Market Expected to Reach $268 Billion In 2026, With A CAGR Of 9.15%
Palm Beach, FL –November 16, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic has affected the healthcare systems globally and also has a significant impact on the cancer therapy... 
Via FinancialNewsMedia
Exposures COVID-19
NASDAQ:SAVA Long Term Investor Notice: Investigation of Potential Wrongdoing at Cassava Sciences, Inc.
San Diego, CA -- (SBWIRE) -- 11/15/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Cassava Sciences, Inc.. 
Via SBWire
Topics Lawsuit
Exposures Financial Legal
Cassava Pops As Cortexyme Dives — Why One Alzheimer's Stock Is 'Back On Track'
An analyst says Cassava is on track, but Cortexyme took another beating Thursday. 
Via Investor's Business Daily
7 Short-Squeeze Stocks Loaded With High-Risk, High-Reward Upside
Here are seven of the top short-squeeze stocks investors may want to keep their eye on, as retail investors lay and wait for the next squeeze. 
Via InvestorPlace
Cassava Sciences Needs Time and Data to Prove Itself Before You Buy
Even as SAVA stock whipsaws in both directions, Cassava's commitment to treating Alzheimer's disease remains as firm and steady as ever. 
Via InvestorPlace
Cassava Is a Sell After Accusations of Data Manipulation
After Cassava was accused of multiple improprieties for its star Simufilam drug, investors should sell the vast majority of their SAVA stock. 
Via InvestorPlace
Short Squeeze Stocks: PROG, SAVA and 3 Others Experts Think Are Ready to Pop
Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching. 
Via InvestorPlace
5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Cassava Sciences Joins Following Short Report
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: 
Via Benzinga
81 Biggest Movers From Yesterday
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on Wednesday. TDH Holdings, Inc. (NASDAQ: PETZ) jumped 79.8... 
Via Benzinga
Why Did Cassava Sciences Stock Jump 49% Today?
Journal of Neuroscience has informed Cassava Sciences Inc (NASDAQ: SAVA) that there is no evidence of data manipulation in an article published in July 2012... 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Jumps 150 Points; NeoPhotonics Shares Spike Higher
Toward the end of trading Thursday, the Dow traded down 0.44% to 35,999.43 while the NASDAQ rose 0.97% to 15,964.55. The S&P also rose, gaining 0.30% to 4,674.44. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Cassava Sciences Shares Are Rising
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher after a review by the Journal of Neuroscience showed there is no evidence of data manipulation in a 2012 company... 
Via Benzinga
S&P 500, Nasdaq Nab More Intraday Highs, Dow Falls Triple Digits
Stocks are mixed midday, with the Dow Jones Industrial Average down triple digits. 
Via Talk Markets
Topics Stocks
Exposures US Equities
SAVA Stock Alert: Why Cassava Sciences Is Rocketing 50% Higher Today
Cassava Sciences just got good news. SAVA stock is soaring as the company celebrates the end of its manipulated data accusations. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Evaxion Biotech (NASDAQ:EVAX) stock moved upwards by 157.5% to $16.74 during Thursday's regular session. Evaxion Biotech's stock is trading at a volume of... 
Via Benzinga
Mid-Day Market Update: Gold Rises 1.7%; Lightspeed Commerce Shares Plunge
Midway through trading Thursday, the Dow traded down 0.25% to 36,068.78 while the NASDAQ rose 0.60% to 15,906.62. The S&P also rose, gaining 0.21% to 4,670.58. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Cassava Stock Soars; Journal Finds No Proof Of Tampered Alzheimer's Data
The journal that published a disputed paper from Cassava said Thursday it found no evidence of data manipulation, leading SAVA stock to soar. 
Via Investor's Business Daily
Mid-Morning Market Update: Markets Mixed; Moderna Lowers Covid-19 Vaccine Sales Outlook
Following the market opening Thursday, the Dow traded down 0.20% to 36,086.70 while the NASDAQ rose 0.83% to 15,942.06. The S&P also rose, gaining 0.40% to 4,679.39. The U.S.... 
Via Benzinga
Topics Stocks
Exposures COVID-19 US Equities
55 Stocks Moving In Thursday's Mid-Day Session
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday. NerdWallet, Inc. (NASDAQ: NRDS) jumped 60% to $28.86 after the... 
Via Benzinga
Cassava Sciences Is on a Bumpy Road to Multibagger Status
Based on analyst estimates for the next ten years, SAVA stock could be worth three times more if its Alzheimer's drug succeeds. 
Via InvestorPlace
71 Biggest Movers From Yesterday
Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales... 
Via Benzinga
SAVA Stock: 8 Things to Know as Cassava Sciences Rockets Higher
As investors bet that Cassava Sciences is on the cusp of a breakthrough with its Alzheimer's treatment, SAVA stock is gaining. 
Via InvestorPlace
What's Up With Cassava Sciences Flying Today?
Cassava Sciences Inc (NASDAQ: SAVA) shares are trading up Tuesday as traders were able to push the stock higher. The stock has been trending on social media sites such... 
Via Benzinga
Artificial Intelligence Could Be About To Replace Your Doctor
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 2, 2021 – The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cassava Stock Could Jump More Than 200 Times
Cassava's Alzheimer's drug appears backed by strong data and plenty of public support. That's a winning combination for SAVA stock. 
Via InvestorPlace
Cassava Sciences’ Stock Remains an Enigma
Cassava Sciences has lost 26% for the month through Oct. 27. Entering October, SAVA stock looked to go on a big run. It did the opposite. 
Via InvestorPlace
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.